Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Beta Cell Biology Consortium Resource Report Resource Website 50+ mentions |
Beta Cell Biology Consortium (RRID:SCR_005136) | BCBC | biomaterial supply resource, cell repository, material resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented May 10, 2017. A pilot effort that has developed a centralized, web-based biospecimen locator that presents biospecimens collected and stored at participating Arizona hospitals and biospecimen banks, which are available for acquisition and use by researchers. Researchers may use this site to browse, search and request biospecimens to use in qualified studies. The development of the ABL was guided by the Arizona Biospecimen Consortium (ABC), a consortium of hospitals and medical centers in the Phoenix area, and is now being piloted by this Consortium under the direction of ABRC. You may browse by type (cells, fluid, molecular, tissue) or disease. Common data elements decided by the ABC Standards Committee, based on data elements on the National Cancer Institute''s (NCI''s) Common Biorepository Model (CBM), are displayed. These describe the minimum set of data elements that the NCI determined were most important for a researcher to see about a biospecimen. The ABL currently does not display information on whether or not clinical data is available to accompany the biospecimens. However, a requester has the ability to solicit clinical data in the request. Once a request is approved, the biospecimen provider will contact the requester to discuss the request (and the requester''s questions) before finalizing the invoice and shipment. The ABL is available to the public to browse. In order to request biospecimens from the ABL, the researcher will be required to submit the requested required information. Upon submission of the information, shipment of the requested biospecimen(s) will be dependent on the scientific and institutional review approval. Account required. Registration is open to everyone., documented on August 1, 2015. Consortium that aims to facilitate interdisciplinary collaborations to advance the understanding of pancreatic islet development and function, with the goal of developing innovative therapies to correct the loss of beta cell mass in diabetes, including cell reprogramming, regeneration and replacement. They are responsible for collaboratively generating the necessary reagents, mouse strains, antibodies, assays, protocols, technologies and validation assays that are beyond the scope of any single research effort. The scientific goals for the BCBC are to: * Use cues from pancreatic development to directly differentiate pancreatic beta cells and islets from stem / progenitor cells for use in cell-replacement therapies for diabetes, * Determine how to stimulate beta cell regeneration in the adult pancreas as a basis for improving beta cell mass in diabetic patients, * Determine how to reprogram progenitor / adult cells into pancreatic beta-cells both in-vitro and in-vivo as a mean for developing cell-replacement therapies for diabetes, and * Investigate the progression of human type-1 diabetes using patient-derived cells and tissues transplanted in humanized mouse models. Many of the BCBC investigator-initiated projects involve reagent-generating activities that will benefit the larger scientific community. The combination of programs and activities should accelerate the pace of major new discoveries and progress within the field of beta cell biology. | RIN, Resource Information Network, pancreatic islet, mouse, beta cell, pancreas, pancreatic development, embryonic stem cell, cell line, genomics, antibody, adenovirus, functional genomics, mouse embryonic stem cell line, mouse strain, protocol, embryonic stem cell line, data sharing, data set, gene expression, gene, pancreatic islet development, pancreatic islet function, basic science, basic research, cell reprogramming, cell regeneration, cell replacement, RRID Community Authority |
is used by: NIF Data Federation is used by: Integrated Animals is used by: NIDDK Information Network (dkNET) is listed by: One Mind Biospecimen Bank Listing is listed by: re3data.org is listed by: Consortia-pedia is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources is listed by: Resource Information Network is related to: dkCOIN is related to: Karolinska Institute; Stockholm; Sweden is related to: University of California at Los Angeles; California; USA is related to: Stanford University; Stanford; California is related to: University of Massachusetts Medical School; Massachusetts; USA is related to: Hebrew University Hadassah Medical School; Jerusalem; Israel is related to: Philipps-University Marburg; Marburg; Germany is related to: Imperial College London; London; United Kingdom is related to: Childrens Hospital of Philadelphia - Research Institute; Pennsylvania; USA is related to: Icahn School of Medicine at Mount Sinai; New York; USA is related to: University of California at San Francisco; California; USA is related to: Massachusetts Institute of Technology; Massachusetts; USA; is related to: Hadassah Medical Center; Jerusalem; Israel is related to: DanStem is related to: Oregon Health and Science University; Oregon; USA is related to: Vanderbilt University; Tennessee; USA is related to: University of Chicago; Illinois; USA is related to: University of Massachusetts; Massachusetts; USA is related to: University of Colorado Boulder; Colorado; USA is related to: Vrije Universiteit Brussel; Brussels; Belgium is related to: University of Geneva; Geneva; Switzerland is related to: University of Pennsylvania Perelman School of Medicine; Pennsylvania; USA is related to: McEwen Centre for Regenerative Medicine is related to: Seattle Childrens Research Institute; Washington; USA is related to: Columbia University; New York; USA is related to: University of Texas Southwestern Medical Center; Texas; USA is related to: Hagedorn Research Institute; Gentofte; Denmark is related to: Howard Hughes Medical Institute is related to: Northwestern University; Illinois; USA is related to: CAMRD is related to: French National Center for Scientific Research is related to: University of California at San Diego; California; USA is related to: University of Pittsburgh; Pennsylvania; USA is related to: University of Copenhagen; Copenhagen; Denmark is related to: Jackson Laboratory is related to: Max Planck Institute for Heart and Lung Research; Bad Nauheim; Germany is related to: Indiana University; Indiana; USA is related to: University of Toronto; Ontario; Canada is related to: Harvard University; Cambridge; United States is related to: Harvard Medical School; Massachusetts; USA is related to: Integrated Manually Extracted Annotation has parent organization: Vanderbilt University; Tennessee; USA is parent organization of: Beta Cell Genomics Ontology |
Type 1 diabetes, Diabetes | NIDDK DK-01-014; NIDDK DK-01-17; NIDDK DK-01-18; NIDDK DK-09-011 |
THIS RESOURCE IS NO LONGER IN SERVICE | nlx_144143 | SCR_005136 | SciCrunch Registry | 2026-10-24 12:49:53 | 60 | ||||||
|
Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Resource Report Resource Website |
Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (RRID:SCR_014384) | GRADE\\t | data or information resource, data set, resource | A comparative study that aims to determine which combination of two medications is best for glycemic control in Type 2 Diabetes, has the fewest side effects, and is the most beneficial for overall health. GRADE is a randomized clinical trial of participants diagnosed with type 2 diabetes within the past 10 years who are already on metformin. Participants will be randomly assigned to 1 of 4 commonly-used glucose-lowering drugs (glimepiride, sitagliptin, liraglutide, and basal insulin glargine), plus metformin, and will be followed for up to 7 years. | glycemic reduction, comparative study, type 2 diabetes, clinical trial, randomized, glimepiride, sitagliptin, liraglutide, and basal insulin glargine, metformin |
is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers |
Type 2 diaberes, Diabetes | NIDDK | Documents for prospective researchers on ancillary studies are available | http://www.niddk.nih.gov/research-funding/research-resources/Pages/default.aspx | SCR_014384 | SciCrunch Registry | Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study | 2026-10-24 12:49:58 | 0 | |||||
|
Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Resource Report Resource Website |
Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology (RRID:SCR_015320) | data or information resource, organization portal, portal | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July,27,2022. Core facility that provides scientific and budgetary oversight for all CCEH activities. This includes training programs, high school summer internships, and and pilot and feasibility program for new projects. | cancer research, administrative support, budgetary oversight, training programs |
is listed by: NIDDK Information Network (dkNET) has parent organization: Fred Hutchinson Cancer Center has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Antibody Technology has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Arnold Library has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Bioinformatics Resource has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Comparative Medicine has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Electron Microscopy has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Experimental Histopathology Shared Resource has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Flow Cytometry has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Genomics Shared Resource has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Glassware Services has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Proteomics Resource has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Research Freezers and Sample Storage Resource has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Scientific Imaging has organization facet: Fred Hutchinson Cancer Research Center Co-operative Center for Excellence in Hematology Specimen Processing/Research Cell Bank is organization facet of: Hematology Centers |
cancer | NIDDK P30DK056465 | THIS RESOURCE IS NO LONGER IN SERVICE | SCR_015922 | SCR_015320 | SciCrunch Registry | 2026-10-24 12:49:59 | 0 | |||||||
|
University of Michigan Center for Gastrointestinal Research Resource Report Resource Website |
University of Michigan Center for Gastrointestinal Research (RRID:SCR_015605) | UMCGR | data or information resource, organization portal, portal | Center whose goal is to investigate signal transduction mechanisms regulating homeostasis and GI disorders. Their approach includes studies on genetics and gene regulation, cellular signaling pathways, receptors and ion channels. | UMCGR, gastrointestinal research, GI functions, homeostasis, cellular signaling pathway, gene regulation |
is listed by: NIDDK Information Network (dkNET) is parent organization of: University of Michigan Center for Gastrointestinal Research Protein Localization, Identification and Folding Core is parent organization of: University of Michigan Center for Gastrointestinal Research In Vivo Animal and Human Studies Core is parent organization of: University of Michigan Center for Gastrointestinal Research Molecular Biology Core is parent organization of: University of Michigan Center for Gastrointestinal Research Microbiome and Metabolomics Core has organization facet: University of Michigan Center for Gastrointestinal Research Protein Localization, Identification and Folding Core has organization facet: University of Michigan Center for Gastrointestinal Research In Vivo Animal and Human Studies Core has organization facet: University of Michigan Center for Gastrointestinal Research Molecular Biology Core has organization facet: University of Michigan Center for Gastrointestinal Research Microbiome and Metabolomics Core is organization facet of: Digestive Disease Centers |
digestive disease | NIDDK P30 DK034933 | Available to affiliated researchers | SCR_015605 | SciCrunch Registry | 2026-10-24 12:50:01 | 0 | |||||||
|
imctools Resource Report Resource Website 10+ mentions Rating or validation data |
imctools (RRID:SCR_017132) | IMCtools | data processing software, software application, software resource | Software Python package that implements preprocessing pipeline for imaging mass cytometry data. Can convert IMC raw files to tiff files that are used as inputs into CellProfiller, Ilastik, Fiji etc. | preprocessing, pipeline, imaging, mass, cytometry, data, convert, IMC, raw, file, TIFF |
has parent organization: University of Zurich; Zurich; Switzerland is a plug in for: Fiji |
European Research Council ; NIDDK UC4 DK108132; PhosphonetPPM and MetastasiX SystemsX grant ; Roche Postdoctoral Fellowship ; SNSF Assistant Professorship grant ; Swiss National Science Foundation |
PMID:29605184 | Free, Available for download, Freely available | https://bodenmillergroup.github.io/imctools/build/html/index.html | SCR_017132 | SciCrunch Registry | imaging mass spectrometry tools | 2026-10-24 12:50:03 | 25 | |||||
|
Chemoproteomic identification and therapeutic validation of proteins of metabolic significance Resource Report Resource Website |
Chemoproteomic identification and therapeutic validation of proteins of metabolic significance (RRID:SCR_015847) | data or information resource, database, portal, project portal | Database portal for a project that aims to discover and characterize new molecular pathways that can be targeted pharmacologically to revert obesity-linked adipocyte defects that drive systemic insulin resistance and type 2 diabetes. It works to identify in tandem physiologically-relevant proteins and chemical tools in order to expedite their functional annotation and therapeutic validation. | diabetes, type II diabetes, compound, genetic model, metabolic disease, molecular pathway, obesity, adipocyte, insulin resistance | has parent organization: Scripps Research Institute | obesity, Diabetes, Type II Diabetes | NIDDK DK099810; NIDDK DK114785 |
Freely available, Public | SCR_015847 | SciCrunch Registry | 2026-10-24 12:50:00 | 0 | ||||||||
|
Monogenic Diabetes Registry Resource Report Resource Website |
Monogenic Diabetes Registry (RRID:SCR_015883) | MDR, NDR, MODYR | data or information resource, database, portal, project portal | Research project that aims to learn more about the number of people who have monogenic diabetes, why and how it happens, and how best to treat it. Any adult or child with a known genetic cause of diabetes may join the MODY Registry. | monogenic, diabetes, neonatal, mody, diabetes research, genetic disease |
is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers has parent organization: University of Chicago; Illinois; USA |
Diabetes, Monogenic Diabetes, Neonatal Diabetes, MODY | NIDDK | Public, Diagnosed individuals may register, Freely available | SCR_015883 | SciCrunch Registry | MODY Registry, Neonatal Diabetes Registry | 2026-10-24 12:50:00 | 0 | ||||||
|
National Glycohemoglobin Standardization Program Resource Report Resource Website 500+ mentions |
National Glycohemoglobin Standardization Program (RRID:SCR_015885) | NGSP | data or information resource, portal, project portal | Project that aims to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes. | glycohemoglobin, diabetes, dcct, ukpds, hba1c, diabetes patient, hemoglobin, a1c |
is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers |
Diabetes | NIDDK UC4 DK096587 | Public | SCR_015885 | SciCrunch Registry | NGSP: National Glycohemoglobin Standardization Program | 2026-10-24 12:50:00 | 932 | ||||||
|
Irritable Bowel Syndrome Outcome Study Resource Report Resource Website |
Irritable Bowel Syndrome Outcome Study (RRID:SCR_001504) | IBSOS | clinical trial, resource | Multi-center placebo-controlled randomized clinical trial to assess the short-term and long-term efficacy of cognitive behavior therapy (CBT) for irritable bowel syndrome (IBS) using two treatment delivery systems: self administered CBT and therapist administered CBT. Long term project goals are to develop an effective self-administered behavioral treatment program that can enhance the quality of patient care, improve clinical outcomes, and decrease the economic and personal costs of one of the most prevalent and intractable gastrointestinal disorders. | gastrointestinal disorder, cognitive behavior therapy, self-management, self-administered |
is listed by: NIDDK Information Network (dkNET) has parent organization: University at Buffalo; New York; USA |
Irritable bowel syndrome | NIDDK 5U01DK077738-07 | PMID:22846389 | Free | nlx_152839 | SCR_001504 | SciCrunch Registry | 2026-10-24 12:52:03 | 0 | |||||
|
Folic Acid for Vascular Outcome Reduction in Transplantation Resource Report Resource Website 1+ mentions |
Folic Acid for Vascular Outcome Reduction in Transplantation (RRID:SCR_001505) | FAVORIT | clinical trial, resource | Multi-center, randomized, double blind controlled clinical trial to determine whether treatment with a standard multivitamin augmented with high doses of folic acid, vitamin B6 and vitamin B12 reduces the rate of cardiovascular disease outcomes in renal transplant recipients relative to participants receiving a similar multivitamin that contains no folic acid. This study hopes to show that by reducing the level of homocysteine in the body, the risk of heart disease is also reduced among kidney transplant patients. | multivitamin, folic acid, vitamin b6, vitamin b12, outcome, homocysteine, adult human, middle adult human, late adult human, vitamin, bibliography |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Cardiovascular disease, Kidney transplant recipient | NIDDK U01DK061700 | PMID:16923411 | Free, Freely available | nlx_152827 | http://www.cscc.unc.edu/favorit/ | http://www.cscc.unc.edu/favorit/favdescrip.htm | SCR_001505 | SciCrunch Registry | Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) | 2026-10-24 12:52:04 | 1 | ||
|
Family Investigation of Nephropathy of Diabetes Resource Report Resource Website |
Family Investigation of Nephropathy of Diabetes (RRID:SCR_001525) | FIND, F.I.N.D. | clinical trial, resource | Multicenter observational study designed to identify genetic determinants of diabetic nephropathy. It is conducted in eleven U.S. clinical centers and a coordinating center, and with four ethnic groups (European Americans, African Americans, Mexican Americans, and American Indians). Two strategies are used to localize susceptibility genes: a family-based linkage study and a case-control study using mapping by admixture linkage disequilibrium (MALD). In the family-based study, probands with diabetic nephropathy are recruited with their parents and selected siblings. Linkage analyses will be conducted to identify chromosomal regions containing genes that influence the development of diabetic nephropathy or related quantitative traits such as serum creatinine concentration, urinary albumin excretion, and plasma glucose concentrations. Regions showing evidence of linkage will be examined further with both genetic linkage and association studies to identify genes that influence diabetic nephropathy or related traits. Two types of MALD studies are being done. One is a case-control study of unrelated individuals of Mexican American heritage in which both cases and controls have diabetes, but only the case has nephropathy. The other is a case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring are genotyped when available to provide haplotype data. The specific goals of this program: * Delineate genomic regions associated with the development and progression of renal disease(s) * Evaluate whether there is a genetic link between diabetic nephropathy and diabetic retinopathy * Improve outcomes * Provide protection for people at risk and slow the progression of renal disease * Help establish a resource for genetic studies of kidney disease and diabetic complications by creating a repository of genetic samples and a database * Encourage studies of the genetics of progressive renal disease | genetic susceptibility, genetic pathway, renal, kidney, outcome, gene, genetics, european-american, african-american, mexican-american, american-indian, linkage association study, admixture linkage disequilibrium, mapping by admixture linkage disequilibrium, serum creatinine, urinary protein excretion, plasma glucose level, blood pressure, blood lipid level, trait, linkage, adult human, male, female, clinical |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
NIDDK 5R01DK053591 | PMID:15642484 | Free, Freely available | nlx_152825 | https://www.niddkrepository.org/studies/find/ | SCR_001525 | SciCrunch Registry | Family Investigation of Nephropathy and Diabetes (F.I.N.D.), Family Investigation of Nephropathy & Diabetes | 2026-10-24 12:52:03 | 0 | ||||
|
HALT PKD Resource Report Resource Website 1+ mentions |
HALT PKD (RRID:SCR_001529) | HALT PKD, HALT-PKD | clinical trial, resource | Consortium established to design and implement clinical trials of treatments that might slow the progressive loss of renal function in Polycystic Kidney Disease (PKD). Two multicenter randomized, double-blind, placebo controlled clinical trials are running concurrently to study the efficacy of renin-angiotensin-aldosterone system blockade on the progression of cystic disease (kidney volume) and on the decline in renal function in autosomal dominant polycystic kidney disease (ADPKD). Study A is to study whether intensive ACE-I/ARB blockade decrease the progression of cystic disease compared to ACE-I monotherapy patients with early disease, relatively preserved renal function, and high-normal BP or hypertension. Study B is to study whether intensive ACE-I/ARB blockade as compared to ACE-I monotherapy slow the decline in kidney function, end-stage of renal disease, or death in the setting of standard blood pressure control in hypertensive patients with moderately advanced disease. | treatment, renal function, lisinopril, placebo, telmisartan, male, female, adolescent, adult human |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Washington University School of Medicine in St. Louis; Missouri; USA |
Polycystic kidney disease, Autosomal dominant polycystic kidney disease | NIDDK 5U01DK062408 | Free, Freely available | nlx_152832 | https://www.niddkrepository.org/studies/halt-pkd/ | http://www.pkd.wustl.edu/pkdtn/ | SCR_001529 | SciCrunch Registry | Polycystic Kidney Disease-Treatment Network | 2026-10-24 12:52:04 | 1 | |||
|
Clinical Islet Transplantation Study Resource Report Resource Website 1+ mentions |
Clinical Islet Transplantation Study (RRID:SCR_001515) | CIT Study | clinical trial, resource | Network of centers to conduct studies of islet transplantation in patients with type 1 diabetes to improve the safety and long-term success of methods for transplanting islets. It is the aim of this trial to improve methods of isolating islets, to improve techniques for the administering those transplanted islets; and to develop approaches to minimize the toxic effects of immunosuppressive drugs required for transplantation. | islet transplantation, islet, insulin, beta cell, pancreas, autoimmune, clinical | is listed by: NIDDK Information Network (dkNET) | Type 1 diabetes, Diabetes | NIDDK U01DK070431 | Free, Freely available | nlx_152840 | SCR_001515 | SciCrunch Registry | Clinical Islet Transplantation Trial, Islet Transplantation Trials for Type 1 Diabetes | 2026-10-24 12:52:03 | 5 | |||||
|
RiVuR Resource Report Resource Website 1+ mentions |
RiVuR (RRID:SCR_001539) | RIVUR | clinical trial, resource | Multicenter, randomized, double-blind, placebo-controlled trial is designed to determine whether daily antimicrobial prophylaxis is superior to placebo in preventing recurrence of urinary tract infection (UTI) in children with vesicoureteral reflux (VUR). The basic eligibility criteria are: (1) age at randomization of at least 2 months, but less than 6 years, (2) a diagnosed first febrile or symptomatic UTI within 42 days prior to randomization that was appropriately treated, and (3) presence of Grade I-IV VUR based on voiding cystourethrogram (VCUG). Patients will be randomly assigned to treatment for 2 years with daily antimicrobial prophylaxis (trimethoprim-sulfamethoxazole) or placebo. The study is designed to recruit 600 children (approximately 300 in each treatment group) over an 18-24 month period. The primary endpoint is recurrence of UTI. In addition, patients will be evaluated for secondary endpoints related to renal scarring and antimicrobial resistance. Scarring will be determined based on renal scintigraphy by 99mTc dimercaptosuccinic (DMSA) scan. Quality of life, compliance, safety parameters, utilization of health resources, and change in VUR will be assessed periodically throughout the study. | child, antimicrobial prophylaxis, placebo, antibiotic, renal scarring, pediatric, trimethoprim-sulfamethoxazole, intervention, kidney, antibiotic resistance, young human, infant, bibliography, clinical, trimethoprim, sulfamethoxazole |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Vesico-ureteral reflux, Urinary tract infection | NIDDK | PMID:19570724 PMID:19018048 PMID:18076937 PMID:19018047 PMID:19086141 |
Free, Freely available | nlx_152848 | http://www.cscc.unc.edu/rivur/ | SCR_001539 | SciCrunch Registry | Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR), Randomized Intervention for Children with Vesicoureteral Reflux, Randomized Intervention for Vesicoureteral Reflux | 2026-10-24 12:52:04 | 1 | |||
|
Type 1 Diabetes Preclinical Testing Program Resource Report Resource Website |
Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) | T1D-PTP, NIDDKT1D-PTP | resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. | testing, therapeutic, clinical, drug, preclinical, therapy, drug development, high-throughput screening, animal model, formulation, pharmacology, toxicology |
is related to: Type 1 Diabetes - Rapid Access to Intervention Development is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152741 | SCR_006861 | SciCrunch Registry | Type 1 Diabetes Preclinical Testing Program (T1D-PtP), NIDDKType 1 Diabetes Preclinical Testing Program | 2026-10-24 12:52:10 | 0 | |||||
|
Functional Dyspepsia Treatment Trial Resource Report Resource Website |
Functional Dyspepsia Treatment Trial (RRID:SCR_006691) | FDTT | clinical trial, resource | Multi-center, randomized, placebo-controlled trial evaluating the tricyclic antidepressant, amitriptyline and the selective serotonin reuptake inhibitor (SSRI), escitalopram to placebo in patients with functional dyspepsia. The purpose of this study is to determine whether amitriptyline and escitalopram are more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidities. | antidepressant, amitriptyline, selective serotonin reuptake inhibitor, escitalopram, placebo |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Functional dyspepsia | NIDDK | PMID:22343090 | nlx_152830 | SCR_006691 | SciCrunch Registry | Antidepressant Therapy for Functional Dyspepsia, Functional Dyspepsia Treatment Trial (FDTT) | 2026-10-24 12:52:10 | 0 | |||||
|
Maryland Genetics of Interstitial Cystitis Resource Report Resource Website |
Maryland Genetics of Interstitial Cystitis (RRID:SCR_006992) | MaGIC | clinical trial, resource | Clinical study that investigated several hundred families with two or more blood relatives with interstitial cystitis in order to understand the molecular genetic basis of this condition. The study sought to find changes in genes that are found far more commonly in family members who have interstitial cystitis than in those who do not have the disease. Identifying these genes should lead to a better understanding of the cause of interstitial cystitis. This is a national study which is conducted by telephone and mail, and in which participants could participate entirely from their home. | male, female, adolescent, adult human, genetics, risk factor, family history, bladder, pain, observational |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Maryland School of Medicine; Maryland; USA |
Interstitial cystitis | NIDDK | nlx_152843 | http://icresearch.umaryland.edu/magic.aspx | SCR_006992 | SciCrunch Registry | Maryland Genetics of Interstitial Cystitis (MaGIC) | 2026-10-24 12:52:10 | 0 | |||||
|
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis Resource Report Resource Website |
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (RRID:SCR_006772) | HUSC | clinical trial, resource | Multi-center, placebo-controlled trial of ursodiol in primary sclerosing cholangitis (PSC). A total of 150 patients with previously untreated PSC without cirrhosis were randomly assigned to receive high doses of ursodiol (20-25 mg/kg/day) or placebo for two years. Patients underwent medical evaluation, endoscopic retrograde cholangiography, and liver biopsy before randomization and again at two-year intervals. The endpoints of therapy were progression of hepatic fibrosis, liver decompensation, liver transplantation, or death. The treatment phase of the study was stopped for futility in June 2008; however, patients continue to be followed. Ongoing mechanistic studies are underway. | treatment, placebo, ursodeoxycholic acid, intervention, randomized, adult human, male, female |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Primary Sclerosing Cholangitis | NIDDK | PMID:19585548 | nlx_152836 | SCR_006772 | SciCrunch Registry | Trial of High-dose Urso in Primary Sclerosing Cholangitis, High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (HUSC), Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis | 2026-10-24 12:52:09 | 0 | |||||
|
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit Resource Report Resource Website |
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) | GLND | clinical trial, resource | Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity. | parenteral nutrition, glutamine, glutamine dipeptide, clinical, outcome, adult human, mortality, nosocomial infection, immune cell function, hospital morbidity, morbidity, intensive care |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Emory University; Georgia; USA |
Critical illness | NIDDK U01DK069322 | PMID:18596310 | nlx_152823 | http://www.sph.emory.edu/GLND | SCR_006806 | SciCrunch Registry | Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients, Efficacy and Mechanisms of GLN Dipeptide in the SICU, Efficacy and Mechanisms of GLN Dipeptide in the SICU (GLND), GLND trial | 2026-10-24 12:52:11 | 0 | ||||
|
Diabetes Control and Complications Trial Resource Report Resource Website |
Diabetes Control and Complications Trial (RRID:SCR_006805) | DCCT | clinical trial, data or information resource, database, resource | Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk | blood glucose, adolescent, young human, middle adult human, longitudinal, eye disease, kidney disease, nerve disease, cardiovascular disease, heart attack, stroke, blood pressure, blood lipid, complication |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository is related to: Epidemiology of Diabetes Interventions and Complications is related to: Epidemiology of Diabetes Interventions and Complications is related to: NIDDK Information Network (dkNET) has parent organization: National Diabetes Information Clearinghouse |
Type 1 diabetes, Diabetes | NIDDK | nlx_152798 | SCR_006805 | SciCrunch Registry | DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study | 2026-10-24 12:52:09 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the NIF Resources search. From here you can search through a compilation of resources used by NIF and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that NIF has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on NIF then you can log in from here to get additional features in NIF such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into NIF you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
Welcome to the Neuroscience Information Framework Project, designed to serve the biomedical research community. NIF maintains the largest searchable collection of neuroscience data, the largest catalog of biomedical resources, and the largest ontology for neuroscience on the web. We welcome all feedback and suggestions and are actively looking for resource providers to make their resources accessible through NIF. Learn about the tools available to help you share your data and discover a dynamic inventory of Web-based neuroscience resources.
